~~<i id='EEAFDD86D8'><strike id='EEAFDD86D8'><tt id='EEAFDD86D8'><pre id='EEAFDD86D8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：knowledge 2025-09-05 11:21:38 - browse：7

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

Wikipedia

hotspot

explore

leisure time

Wikipedia

AdobeLONDON—Datafromhalfamillionpeople’swholegenomesequencesarenowavailabletoresearchersworldwide,as

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Cholera vaccine supply gets boost as demand surges globally

Cholera vaccine supply gets boost as demand surges globally

Mayo Clinic plans $5B tech

Q&A: Jennifer Adair on making gene therapy available globally

Health care needs a new profession: neuroimaging counseling

knowledge

explore

Wikipedia

Heart attack and stroke risk calculators need revising

30 years of 'Listening to Prozac'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC director unscathed in first congressional testimony

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Wildfire smoke exposes gaps in outdoor worker protections

Cell therapy fails to slow type 1 diabetes, but safety is established

Duchenne breakthrough therapy leaves behind pioneering families

Q&A: Jennifer Adair on making gene therapy available globally

hotspot

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

MultiPlan and major insurers sued for alleged medical price

Diagnostic tests are hitting their mathematical limits

Disappointing trial forces Pfizer to pivot on obesity medicine plans

U.K. Biobank has 500,000 peoples' genome sequences available

Flagship Pioneering launches a new biotech in two countries

explore

leisure time

leisure time

Wikipedia